Zydus Lifesciences Q4 net profit rises 18% on strong US, India sales

New Delhi: Zydus Life Sciences reported an 18% year-on-year (YoY) rise in net profit to Rs 1,390.5 crore, (adjusted for exceptional item) for the quarter ended March 31, 2025, driven by robust growth across its US formulations, India branded generics, and consumer wellness businesses.

Consolidated revenue from operations rose 18% YoY to Rs 6,528 crore, while EBITDA surged 30% to Rs 2126 crore, with margins expanding 310 basis points to 32.6%.

For the full fiscal year, revenue climbed 19% to Rs 23,242 crore, and net profit (adjusted for exceptional items) increased 23% to Rs 4745 crore. The company ended the year with a net cash position of Rs 4884 crore, up from Rs 856 crore a year earlier.

“We are happy to conclude FY 2025 on a strong note, with all our businesses surpassing our growth expectations,” said Dr. Sharvil Patel, Managing Director. “The commercial success of our extensive product portfolio combined with operating leverage has significantly bolstered profitability and financial health. We made meaningful progress in our differentiated pipeline and added new capabilities to ensure sustainable growth.”

Zydus invested Rs 1856 crore in R&D during FY25 (8% of revenue), advancing its pipeline in new chemical entities (NCEs), vaccines, and specialty products. The capex spend in FY25 was Rs 1214 crore.

The notable developments include USFDA approval for Phase II(b) trials of Usnoflast for ALS, with Orphan Drug Designation. Progress in Saroglitazar Magnesium trials for PBC and NASH. Initiation of a combination vaccine for shigellosis and typhoid with Gates Foundation support.

The company said it has completed USFDA inspections at multiple facilities with no observations. One site received six observations unrelated to data integrity, which the company is addressing.